Not quite three weeks after triggering a medico-commercial earthquake with the ENHANCE trial results, Schering-Plough and Merck have yet to win back three key constituencies: prescribers, patients and investors. The stakes for not doing so are enormous. But more importantly for the industry as a whole, ENHANCE is the latest and strongest sign that the cornerstone on which blockbuster franchises are built-simple, compelling and easy-to-verify measures of treatment success--is crumbling in the face of biological complexity. And that means that primary-care success is going to get a lot more expensive.
Not quite three weeks after triggering a medico-commercial earthquake with the ENHANCE trial results, Schering-Plough Corp. and Merck & Co. Inc. have yet to win back three key constituencies: prescribers, patients, and investors. The stakes for not doing so are enormous.
But more importantly for the industry as a whole, ENHANCE is the latest and strongest sign that the cornerstone on...
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Digital clinical trials, a trend sparked by the COVID-19 pandemic that has held the biopharma industry’s interest, are changing the way patients interact with research and improving access, says Medable’s CEO.
INFOGRAPHIC: Deal volume for both M&A and alliances fell in 2023, but average valuations rose appreciably. Antibody-drug conjugates for cancer drove high-value acquisitions and partnerships.
Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
